Abstract
Leukemia stem cells (LSC) are thought to be the basis of leukemia progression since they are highly resistant to conventional chemotherapy. LSC isolation is critical in experimental studies, drug development, and application. Due to their likely hematopoietic stem cell (HSC) origin, LSCs have surface antigens that are similar to HSC. Surface markers such as CD34, CD123, CD133, and CD33 have been used extensively to assess LSCs. LSCs could be separated from other cells using magnetic selection (MS) or flow cytometry selection (FCS) methods using these markers. Understanding the role of LSCs in cancer progression and how to therapeutically target them in vitro and in vivo is critical for the development of LSC-targeting drug candidates. In this chapter, we set out to describe the primary human LSC purification and characterization processes used on patient samples with leukemia and lymphoma.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Juliusson G, Hough R (2016) Leukemia. pp 87–100
Polak A, Bialopiotrowicz E, Krzymieniewska B et al (2020) SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism. Cell Death Dis 11:956
Hanekamp D, Cloos J, Schuurhuis GJ (2017) Leukemic stem cells: identification and clinical application. Int J Hematol 105(5):549–557
Gupta PB, Chaffer CL, Weinberg RA (2009) Cancer stem cells: Mirage or reality? Nat Med 15(9):1010–1012
Vormoor J, Lapidot T, Pflumio F et al (1994) Immature human cord blood progenitors engraft and proliferate to high levels in severe combined immunodeficient mice. Blood 83(9):2489–2497
Weissman I (2005) Stem cell research: Paths to cancer therapies and regenerative medicine. J Am Med Assoc 294(11):1359–1366
Passegué E, Wagers AJ, Giuriato S et al (2005) Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates. J Exp Med 202(11):1599–1611
Okada Y, Feng Q, Lin Y et al (2005) hDOT1L links histone methylation to leukemogenesis. Cell 121(2):167–178
Wang J, Iwasaki H, Krivtsov A et al (2005) Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. EMBO J 24(2):368–381
Jordan CT, Upchurch D, Szilvassy SJ et al (2000) The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stems cells. Leukemia 14:1777–1784
Bernt KM, Armstrong SA (2009) Leukemia stem cells and human acute lymphoblastic leukemia. Semin Hematol 46(1):33–38
Shultz LD, Ishikawa F, Greiner DL (2007) Humanized mice in translational biomedical research. Nat Rev Immunol 7:118–130
Lapidot T, Sirard C, Vormoor J et al (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367(6464):645
Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3(7):730–737
Chung SS, Park CY (2014) Acute myeloid leukemia stem cells-updates and controversies. Cancer Stem Cells:143–160
Ng SWK, Mitchell A, Kennedy JA et al (2016) A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature 540:433–437
Buss EC, Ho AD (2011) Leukemia stem cells. Int J Cancer 129(10):2328–2336
Terwijn M, Zeijlemaker W, Kelder A et al (2014) Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. PLoS One 9(9):e107587
Gentles AJ, Plevritis SK, Page P et al (2010) Association of a leukemic stem cell gene in acute myeloid leukemia. JAMA 304(24):2706–2715
Jin L, Lee EM, Ramshaw HS et al (2009) Monoclonal antibody-mediated targeting of CD123, IL-3 receptor α chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 5(1):31–42
Lechman ER, Gentner B, Ng SWK et al (2016) MiR-126 regulates distinct self-renewal outcomes in normal and malignant hematopoietic stem cells. Cancer Cell 29(2):214–228
Taussig DC, Vargaftig J, Miraki-Moud F et al (2010) Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34- fraction. Blood 115(10):1976–1984
Acknowledgments
This study was supported by funds provided by Gilead Sciences International Hematology and Oncology program. NM and FK were supported by “Gilead ile Hayat Bulan Fikirler.”
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Meriç, N., Kocabaş, F. (2023). Primary Human Leukemia Stem Cell (LSC) Isolation and Characterization. In: Turksen, K. (eds) Stem Cells and Lineage Commitment. Methods in Molecular Biology, vol 2736. Humana, New York, NY. https://doi.org/10.1007/7651_2023_497
Download citation
DOI: https://doi.org/10.1007/7651_2023_497
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-3536-0
Online ISBN: 978-1-0716-3537-7
eBook Packages: Springer Protocols